OSE Immunotherapeutics 관리

관리 기준 확인 3/4

OSE Immunotherapeutics CEO는 Nicolas Poirier, Jan2016 에 임명되었습니다 의 임기는 8.92 년입니다. 총 연간 보상은 € 440.10K, 68.2% 로 구성됩니다. 68.2% 급여 및 31.8% 보너스(회사 주식 및 옵션 포함). 는 € 2.42M 가치에 해당하는 회사 주식의 1.58% 직접 소유합니다. 2.42M. 경영진과 이사회의 평균 재임 기간은 각각 6.5 년과 2.5 년입니다.

주요 정보

Nicolas Poirier

최고 경영자

€440.1k

총 보상

CEO 급여 비율	68.2%
CEO 임기	8.9yrs
CEO 소유권	1.6%
경영진 평균 재임 기간	6.5yrs
이사회 평균 재임 기간	2.5yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Nicolas Poirier 의 보수는 OSE Immunotherapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	€46m
Mar 31 2024	n/a	n/a	€12m
Dec 31 2023	€440k	€300k	-€23m
Sep 30 2023	n/a	n/a	-€25m
Jun 30 2023	n/a	n/a	-€28m
Mar 31 2023	n/a	n/a	-€23m
Dec 31 2022	€1m	n/a	-€18m
Sep 30 2022	n/a	n/a	-€13m
Jun 30 2022	n/a	n/a	-€7m
Mar 31 2022	n/a	n/a	-€12m
Dec 31 2021	€18k	n/a	-€17m
Sep 30 2021	n/a	n/a	-€21m
Jun 30 2021	n/a	n/a	-€25m
Mar 31 2021	n/a	n/a	-€21m
Dec 31 2020	€19k	n/a	-€17m
Sep 30 2020	n/a	n/a	-€12m
Jun 30 2020	n/a	n/a	-€8m
Mar 31 2020	n/a	n/a	-€6m
Dec 31 2019	€9k	n/a	-€5m

보상 대 시장: Nicolas 의 총 보상 ($USD 459.20K ) UK 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 722.49K ).

보상과 수익: Nicolas 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Nicolas Poirier (42 yo)

8.9yrs

테뉴어

€440,100

보상

Dr. Nicolas Poirier, PhD, has been the Scientific Director of OSE Immunotherapeutics SA since 2016 and serves as its Director from June 26, 2019 and also serves as its General Director & Chief Executive Of...

리더십 팀

이름	위치	테뉴어	보상	소유권
Nicolas Poirier	General Director	8.9yrs	€440.10k	1.58% € 2.4m
Anne-Marie Costantini	Founder & Director of Development & Strategy	12.9yrs	€412.50k	9.23% € 14.2m
Anne-Laure Autret-Cornet	CFO, Administrative & Financial Director and Employee Shareholder Representative Director	8.6yrs	데이터 없음	데이터 없음
Alexis Peyroles	Consultant	2.9yrs	€586.59k	데이터 없음
Alain Chatelin	Medical Director	no data	데이터 없음	데이터 없음
Bérangère Vasseur	Chief Medical Officer Immuno-Oncology	6.9yrs	데이터 없음	데이터 없음
Julien Perrier	Chief Commercial Officer	6yrs	데이터 없음	데이터 없음
Linda Lebon	Chief Regulatory Officer	3yrs	데이터 없음	데이터 없음
Silvia Comis	Head of Clinical Development	3yrs	데이터 없음	데이터 없음
Jean-Jacques Mention	Chief Business Officer	no data	데이터 없음	데이터 없음

6.5yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: 0RAD 의 관리팀은 노련하고 경험 (평균 재직 기간 6.5 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Nicolas Poirier	General Director	5.5yrs	€440.10k	1.58% € 2.4m
Anne-Laure Autret-Cornet	CFO, Administrative & Financial Director and Employee Shareholder Representative Director	1.5yrs	데이터 없음	데이터 없음
Maryvonne Hiance	Vice Chairwoman	8.6yrs	€25.71k	1.95% € 3.0m
Bernard Malissen	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Sophie Brouard	Director of External Affairs & Member of the Scientific Advisory Board	2.5yrs	€25.71k	데이터 없음
Charles Serhan	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Brigitte Dreno	Independent Director	7.5yrs	€21.43k	데이터 없음
Didier Hoch	Independent Chairman of the Board of Directors	8.6yrs	€28.57k	데이터 없음
Wolf-Herve Fridman	Chairman of the Scientific Board	11.1yrs	데이터 없음	데이터 없음
Jennifer Wargo	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Myriam Merad	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Eric Leire	Independent Director	1.5yrs	€15.00k	데이터 없음

2.5yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: 0RAD 의 이사회는 경험(평균 재직 기간 2.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/23 18:38
장 마감 주가	2024/12/20 00:00
수익	2024/06/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

OSE Immunotherapeutics SA 8 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Olga Smolentseva	Bryan Garnier & Co
David Seynnaeve	Degroof Petercam
Laura Roba	Degroof Petercam

OSE Immunotherapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

OSE Immunotherapeutics SA, Annual General Meeting, Jun 19, 2024

High number of new directors

High number of new directors

OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director

OSE Immunotherapeutics SA, Annual General Meeting, Jun 22, 2023

OSE Immunotherapeutics SA Appoints Nicolas Poirier as Chief Executive Officer

Recent updates

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 19%

Investor sentiment improves as stock rises 18%

First half 2024 earnings released: EPS: €2.63 (vs €0.64 loss in 1H 2023)

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

OSE Immunotherapeutics Presents Preclinical Data on Mrna Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders At the Focis Annual Meeting, San Francisco

Forecast breakeven date moved forward to 2024

OSE Immunotherapeutics SA, Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: €1.18 loss per share (vs €0.96 loss in FY 2022)

OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors

New minor risk - Share price stability

New minor risk - Shareholder dilution

OSE Immunotherapeutics SA and Nantes University Hospital Presents Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

Ose Immunotherapeutics Sa Announces First Clinical Results for Bi 770371, A Novel Anti-Sirpa Monoclonal Antibody

First half 2023 earnings released: €0.64 loss per share (vs €0.11 loss in 1H 2022)

Forecast breakeven date moved forward to 2024

New major risk - Financial position

High number of new directors

OSE Immunotherapeutics SA Announces Publication in Frontiers in Immunology on Ose-230, Its Novel Agonist Therapy in Chronic Inflammation

OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation

OSE Immunotherapeutics SA Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist

High number of new directors

OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director

OSE Immunotherapeutics SA Presents Clinical Abstracts on Tedopi at the ASCO 2023 Annual Meeting

OSE Immunotherapeutics SA, Annual General Meeting, Jun 22, 2023

OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announces Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi in Advanced Pancreatic Cancer

Forecast to breakeven in 2025

Full year 2022 earnings released: €0.96 loss per share (vs €0.93 loss in FY 2021)

OSE Immunotherapeutics SA Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas

OSE Immunotherapeutics SA Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting

Ose Immunotherapeutics Announces Publication of Peer-Reviewed Data on Clec-1

Servier and OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome

OSE Immunotherapeutics SA Updates on Tedopi®, Cancer Vaccine as Potential New Standard of Care in Non-Small Cell Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Appoints Nicolas Poirier as Chief Executive Officer

First half 2022 earnings released: €0.11 loss per share (vs €0.64 loss in 1H 2021)

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

OSE Immunotherapeutics SA Appoints Alexis Vandier as Chief Executive Officer

OSE Immunotherapeutics SA, Annual General Meeting, Jun 23, 2022

OSE Immunotherapeutics SA Appoints its International Scientific Advisory Board

Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPa Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology

OSE Immunotherapeutics SA Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer Immunotherapy

OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy

No longer forecast to breakeven

OSE Immunotherapeutics SA to Report Fiscal Year 2021 Results on Mar 30, 2022

Boehringer Ingelheim and OSE Immunotherapeutics to Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPa Inhibitor BI 765063 in Advanced Solid Tumors

OSE Immunotherapeutics SA Appoints Alexandre Lebeaut as Independent Member of the Board of Directors

OSE Immunotherapeutics SA Announces Acceptance of the US Investigational New Drug Application Obtained by Veloxis Pharmaceuticals, Inc., Its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients

OSE Immunotherapeutics SA Announce the Continuation of Its Phase 2 Trial Testing Anti-Il-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis After the Interim Futility Analysis

OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, Its Multi-Target T-Cell Anti-COVID Vaccine

First half 2021 earnings released: €0.64 loss per share (vs €0.21 loss in 1H 2020)

OSE Immunotherapeutics SA to Present Phase 1 Results with First-In-Class Sirpa Inhibitor Bi 765063 in Advanced Solid Tumors At Esmo 2021

OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi in Combination with Pembrolizumab in Ovarian Cancer

Servier and OSE Immunotherapeutics SA Announces Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

OSE Immunotherapeutics SA Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study

Ose Immunotherapeutics and the Fort Foundation Announce Initiation of A Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (Nivolumab) in Non-Small Cell Lung Cancer

OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine

OSE Immunotherapeutics SA and Boehringer Ingelheim to Present Positive Phase 1 Results with First-In-Class Sirpa Inhibitor Bi 765063 in Advanced Solid Tumors At Asco 2021

Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA (ENXTPA:OSE).

OSE Immunotherapeutics Sa and ARCAGY - GINECO Announces Initiation of A Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer

OSE Immunotherapeutics SA to Present New Data Reflecting Expansion and Progress on Its Immuno-Oncology and Inflammation Preclinical Portfolio At the 2021 Aacr Annual Meeting

OSE Immunotherapeutics SA Announces Granting of First European Patent Protecting Anti-Il-7 Receptor Antagonist OSE-127/S95011

OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics

OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011

OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011

OSE Immunotherapeutics Receives €5.2 Million in Public Funding for the Clinical Development of CoVepiT, its Second Generation COVID-19 Vaccine